Nivolumab-IRDye800
Phase 1
Nivolumab-IRDye800 is one of 37 therapeutic programs targeting Brain Cancer. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
36
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
26 competitors in Brain Cancer
#DrugCompanyPhaseTrials
1Actos
TakedaApproved
Jevtana
SanofiApproved
Opdivo
Bristol-Myers SquibbPhase 3
Tarceva
OOSI Pharmaceuticals
Approved
Trisenox
CCephalon
Approved
Glucophage
EMD SeronoApproved
Decadron
AAspen Global Incorporated
Approved
Photofrin
PPinnacle Biologics Inc.
Approved
Aloxi
AAvyxa
Approved
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Nivolumab-IRDye800. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]
- Company
- EEben Rosenthal